Proteomics International

What Proteomics International does

Proteomics International is a Perth-based medical technology company founded in 2001 and listed on the ASX (ticker: PIQ) that develops proteomics-based diagnostic tests for the early detection and prediction of disease. The company's core technology uses mass spectrometry to identify proprietary protein biomarker panels in blood, which are combined into diagnostic algorithms delivered through its PromarkerHub software platform. Lead commercial product PromarkerD is a predictive blood test for diabetic kidney disease, with pipeline products including PromarkerEso (esophageal cancer), PromarkerEndo (endometriosis), and OxiDx (oxidative stress). PromarkerHub uses traditional statistical methods (logistic regression with fixed coefficients) rather than AI/ML models, prioritizing regulatory interpretability.

The company operates a hybrid business model combining licensing and distribution partnerships (notably an exclusive US license with Sonic Healthcare, plus regional partners Atturos for Europe, Patia for Mexico, and PrismHealthDx for Asia-Pacific), direct laboratory and analytical services (including pharmacokinetics and biomarker discovery for clients such as Avance Clinical and Sironax), and a direct-to-consumer channel via MyTest.health. The company holds patents in 13+ jurisdictions and maintains regulatory certifications including CAP, CLIA, ISO 13485, ISO 17025, CE Mark, and TGA, with CAP accreditation for its US Reference Laboratory secured in December 2025.

The company's customer base is concentrated, with revenue showing significant quarter-to-quarter volatility driven by individual large contracts (Q3 2025 revenue of A$1.9M was approximately seven times Q3 2024's A$253k, materially influenced by a single UWA analytical services contract). With 11-50 employees, recent product launches, and an active international expansion program, Proteomics International sits at an early commercial stage transitioning from analytical services revenue toward scaled diagnostic product sales, particularly through the US Sonic Healthcare channel.

Name

Proteomics International

Legal name

Proteomics International Laboratories Ltd

Website

https://proteomics.com.au

Company type

Public

Founded year

2001

Operating status

Operating

Headcount range

11–50 employees

Short description

Proteomics International is a Perth-based medical technology company developing proprietary proteomics-based blood diagnostic tests for early disease prediction in diabetes, cancer, and endometriosis, commercialized via licensing partners, laboratory services, and direct-to-consumer channels.

Ownership category

akta.pro rank

Product category

Proteomics Diagnostics

NAICS

Medical Laboratories (621511), Research and Development in Biotechnology (except Nanobiotechnology) (541714), In-Vitro Diagnostic Substance Manufacturing (325413)

SIC

Services-Medical Laboratories (8071), Services-Testing Laboratories (8734), Services-Commercial Physical & Biological Research (8731), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Proteomics & Mass Spectrometry Services (HLAGANAB)

akta.pro secondary industries

Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity) (HLAGAAAD), Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays) (HLAAAMAC), DMPK / ADME & Bioanalysis (HLAGAFAC)

Keywords

• Proteomics diagnostics
• Predictive blood tests
• Biomarker discovery services
• Clinical analytical services
• Mass spectrometry testing

Headquarters

HQ city

Perth

HQ country

Australia

HQ region

Oceania

Offices4 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

1. Diagnostic Test Sales: Revenue from sales of Promarker branded diagnostic tests through direct laboratory services and licensing agreements with regional partners.
2. Analytical Services: Cutting-edge accredited analytical services on commercial scale including pharmacokinetic testing, biomarker discovery and validation, biosimilars/biologics drug characterisation, and specialist protein testing. ISO 17025 accredited.
3. Licensing Royalties: Ongoing royalties from licensing agreements with partners such as Sonic Healthcare USA, Atturos (Europe), Patia (Mexico), and other international distributors.
4. R&D Tax Incentives: Australian Government R&D Tax Incentive rebates for eligible research and development expenditure. Received $2.2M rebate in November 2025.

Pricing tiers

Go-to-market motion2 records

Distribution channels6 records

Marketing channels6 records

Core offering

Proteomics International develops and commercializes proprietary protein biomarker-based blood tests (the Promarker® platform, including PromarkerD for diabetic kidney disease, PromarkerEso for esophageal adenocarcinoma, PromarkerEndo for endometriosis, and OxiDx for oxidative stress) alongside ISO 17025-accredited analytical services (pharmacokinetic testing, biomarker discovery and validation, and biosimilars/biologics drug characterization). Its core revenue comes from licensing these diagnostic tests to healthcare providers and regional partners (e.g., Sonic Healthcare USA, Atturos, Patia), operating its own CLIA/CAP-accredited reference laboratories in the US and Australia, and selling professional analytical services to pharmaceutical and biotech clients.

Product overview

Proteomics International operates a platform-plus-products architecture centered on its Promarker® proteomics platform. The core offering consists of four diagnostic products: PromarkerD (diabetic kidney disease prediction), PromarkerEso (esophageal cancer detection), PromarkerEndo (endometriosis diagnosis), and OxiDx (oxidative stress). These products are supported by the PromarkerHub cloud-based analysis platform which runs proprietary algorithms to calculate risk scores. Additionally, the company offers analytical services (pharmacokinetics, biomarker discovery, biosimilars characterization) as a revenue stream that complements product development. All testing is powered by the company's proteomics expertise - the industrial-scale study of protein structure and function.

Differentiator

Problem solved

Functional benefit

Brands

• PromarkerD: World-first predictive blood test for diabetic kidney disease (DKD), predicting the onset up to four years before symptoms appear.
• PromarkerEso
• PromarkerEndo
• OxiDx
• Promarker Hub
• MyTest

Products and services

• PromarkerD A world-first blood test that predicts the risk of diabetic kidney disease (DKD) up to four years before symptoms appear by analysing protein biomarkers combined with clinical factors in a proprietary algorithm to calculate a risk score. Licensed in the US exclusively to Sonic Healthcare USA, distributed regionally via Atturos (Europe), Patia (Mexico) and PrismHealthDx, and available direct-to-consumer through MyTest.health in Australia and the company's US CLIA/CAP-accredited laboratory. Patented in the US, Europe, Japan, China, India, Hong Kong, Russia, Indonesia, Brazil, Canada, Singapore and Australia.
• PromarkerEso A blood test that detects specific protein changes (proteomic biomarkers) with high accuracy to rule out esophageal adenocarcinoma (EAC) in patients with chronic reflux, with 99.9% negative predictive value and 91.4% sensitivity. Intended for gastroenterologists and GPs managing GORD patients as a non-invasive rule-out ahead of endoscopy, with US launch planned for 2026 following US patent grant and CAP accreditation.
• PromarkerEndo A first-in-class blood test validated to diagnose endometriosis, including in early stages of the disease, using protein biomarkers to enable non-invasive diagnosis without surgical laparoscopy. In development under an expanded University of Melbourne and Royal Women's Hospital research collaboration, with commercialisation grant funding in place; not yet commercially launched.
• OxiDx A diagnostic product for oxidative stress measurement and a platform technology within the company's pipeline of novel diagnostic tests, leveraging the same proprietary proteomics expertise used in the Promarker® portfolio.
• PromarkerHub A cloud-based results analysis platform that runs proprietary algorithms for each Promarker test, combining biomarker and clinical factors in pre-defined logistic regression equations with fixed coefficients to determine risk scores. Marketed as a CE Marked software IVD (PromarkerD Hub) supporting clinical decision-making, not an AI system.
• Analytical Services Cutting-edge, ISO 17025-accredited analytical services delivered on a commercial scale to pharmaceutical and biotech clients, including pharmacokinetic testing, biomarker discovery and validation, biosimilars/biologics drug characterisation, and specialist protein testing. Underpins enterprise contracts such as the A$243,000 Avance Clinical pharmacokinetic engagement and the A$409,000 Sironax Ltd Phase I clinical trial contract.

Quantifiable outcome

• PromarkerD correctly predicted 86% of patients who developed CKD within four years in 447-patient study
• +7 more outcomes

Named customers10 records

Segments6 records

Ideal customer profiles5 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Scale indicators12 records

Recent moves7 records

Expansion highlights5 records

Broad incumbents

• Exact Sciences: Commercial-stage diagnostics leader in non-invasive cancer screening (Cologuard, Oncotype); relevant as a peer in blood-based and biomarker-based diagnostic test commercialization, payor engagement, and US go-to-market scale-up.
• Myriad Genetics: Established molecular diagnostics company with multi-product portfolio (hereditary cancer, pharmacogenomics, prenatal); relevant as a small-to-mid-cap public peer pursuing predictive blood-based diagnostics with US payor coverage.
• Olink Holding: Provides high-throughput proteomics platforms (Olink Explore, Target) widely used in biomarker discovery and translational research; a relevant technology peer given Proteomics International's LC-MS biomarker discovery infrastructure.
• Bio-Techne: Diversified life-science tools and diagnostics company with proteomics reagents, biomarker assay kits, and diagnostic offerings (e.g., ExoDx); comparable as a protein-based tools + diagnostics peer with global reach.
• SomaLogic (now part of Standard BioTools): Operates a large-scale proteomics platform (SomaScan) used for biomarker discovery and clinical research, with growing IVD/health offerings; comparable in core proteomics technology and biomarker services to Proteomics International's discovery platform.
• Natera: Public diagnostics company commercializing blood-based tests across oncology and women's health (Signatera, Empower, Vistara); directly comparable to the endometriosis (PromarkerEndo) and oncology (PromarkerEso) development ambitions.
• Eurofins Scientific: Global laboratory services group with extensive bioanalytical, PK, and clinical diagnostics capabilities; relevant peer to Proteomics International's ISO 17025 analytical services business (PK testing, biosimilar characterization).

Direct peers

• Biodesix: Proteomics/multi-omic blood-based diagnostic company with a portfolio of lung and broader oncology tests using mass spectrometry and proprietary algorithms; similar proteomics discovery-to-IVD commercialization model and small-cap public profile.
• Renalytix AI: Commercial-stage diagnostics company with KidneyIntelX, a blood-based test that predicts kidney disease progression in type 2 diabetes — directly comparable to PromarkerD in product, target patient population, and commercial pathway (US reimbursement, payor engagement).

Others

• Sonic Healthcare: Global diagnostic pathology/laboratory services provider and exclusive US licensee of PromarkerD; both partner and channel-relevant comparable given the integrated laboratory + commercial-distribution role Sonic plays for Proteomics International in the US market.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/proteomics_int
• YouTubeyoutube.com/@proteomicsinternational
• Facebookfacebook.com/mytest.health
• LinkedInlinkedin.com/company/proteomics-international

Compliance9 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds5 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Proteomics International